Curasight is a clinical-stage radiopharmaceutical company advancing uTREAT®, a first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat aggressive solid tumors across multiple indications. uTREAT® is supported by the clinically validated imaging agent uTRACE®, built on the same uPAR-targeting ligand, enabling a differentiated and de-risked theranostic approach.
uPAR (urokinase-type plasminogen activator receptor) is broadly expressed in aggressive cancers and plays a central role in tumor invasion, angiogenesis, and metastasis. By focusing on this validated and widely expressed target, Curasight is pursuing a therapeutic strategy across multiple high-unmet-need solid tumors using a shared biological target and targeting ligand.
One target. One therapy. A pipeline-in-a-drug across aggressive solid tumors.
